Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced that the underwriters of its October 22, 2010 initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of Aegerion's common stock at $9.50 per share, less underwriting discounts and commissions. The option was granted in connection with Aegerion's initial public offering of 5,000,000 shares. The over-allotment option is expected to close on November 2, 2010, subject to customary closing conditions.
Including the over-allotment shares, a total of 5,750,000 shares will have been sold in the offering, resulting in net proceeds of approximately $48.8 million, after deducting underwriting discounts and commissions and estimated offering expenses.
The joint book-running managers of the initial public offering were Leerink Swann LLC and Lazard Capital Markets LLC. The co-managers were Needham & Company, LLC, Canaccord Genuity Inc. and Collins Stewart LLC.
A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission (SEC) on October 22, 2010.
Aegerion Phamaceuticals, Inc.